Abstracts tagged "Clinical Response"

Abstract Number: 591 • 2018 ACR/ARHP Annual Meeting
Evaluation of MRI Ramris Score and Clinical Response in Patients with ACPA Positive Undifferentiated Arthritis Treated with Infliximab Versus Placebo
Thomas Kirchgesner¹, Bruno Vande Berg¹, Tatiana Sokolova², Laurent Meric de Bellefon², Adrien Nzeusseu Toukap³, Maria Stoenoiu⁴ and Patrick Durez², ¹Musculoskeletal Imaging Unit, Musculoskeletal Imaging Unit - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ³Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁴Rheumatology department, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Patients (Pts) with Undifferentiated Arthritis (UA), positive for ACPA antibodies are at high risk of progressing to Rheumatoid Arthritis (RA). TNF play a key…
Abstract Number: 662 • 2018 ACR/ARHP Annual Meeting
Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab for up to 3 Years
Désirée van der Heijde¹, Vinod Chandran², Roy Fleischmann³, Olivier Benichou⁴, Suchitrita Rathmann⁴ and Catherine Shuler⁴, ¹Leiden University Medical Centre, Leiden, Netherlands, ²Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE), an IL-17A antagonist, was shown to be superior to placebo (PBO) in inhibiting the progression of structural joint damage in patients (pts)…
Abstract Number: 686 • 2018 ACR/ARHP Annual Meeting
Five-Year Efficacy and Safety of Apremilast Treatment in Subjects with Psa: A Pooled Analysis of the 3 Phase III Studies
Arthur Kavanaugh¹, Dafna D Gladman², Christopher J. Edwards³, Georg Schett⁴, Benoit Guerette⁵, Nikolay Delev⁵, Lichen Teng⁵, Maria Paris⁵ and Philip J. Mease⁶, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Southampton, Southampton, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen, Nürnberg und Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Celgene Corporation, Summit, NJ, ⁶Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Long-term apremilast (APR) efficacy and safety were evaluated for up to 5 yrs in adults with active PsA in the phase III PALACE 1-3…
Abstract Number: 1408 • 2018 ACR/ARHP Annual Meeting
Using Patient Reported Outcomes at Point of Care in Immune Mediated Diseases: Minimal Clinically Important Differences
M. Elaine Husni¹, Chad Deal², Leonard H. Calabrese³, Greg Strnad⁴, James Bena⁵ and Abby Abelson⁶, ¹Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Shaker Heights, OH, ³Rheumatology, Cleveland Clinic, Cleveland, OH, ⁴Cleveland Clinic, Cleveland, OH, ⁵Quantitative Health Science, QHS Cleveland Clinic, Cleveland, OH, ⁶Department of Rheumatologic & Immunologic Disease, Cleveland Clinic, Cleveland, OH
Background/Purpose: Patient reported measures of global health and disease activity are increasingly used in routine care; however, detecting meaningful change in clinical status (responsiveness) is difficult…
Abstract Number: 1544 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Safety and Efficacy in the Treatment of Rheumatoid Arthritis in a Central/Eastern European Subpopulation
Jiri Vencovsky¹, Janusz Badurski², Šárka Forejtová¹, Olga Lukáčová³, Mykola Stanislavchuk⁴, Daniela Yaneva-Bichovska⁵, Harry Shi⁶, Radu Vasilescu⁷, Tatjana Lukic⁸ and Martin Kabina⁹, ¹Institute of Rheumatology, Prague, Czech Republic, ²Centre of Osteoporosis and Osteoarticular Diseases, Bialystok, Poland, ³National Institute for Rheumatic Diseases, Piešťany, Slovakia, ⁴Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine, ⁵Medical Centre Synexus, Sofia, Bulgaria, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Regional Medical Europe, Brussels, Belgium, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Innovative Health, Prague, Czech Republic
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post hoc analysis assessed tofacitinib safety and efficacy in the Central…
Abstract Number: 2285 • 2018 ACR/ARHP Annual Meeting
Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Takayuki Kishi^1,2, William Warren-Hicks³, Nastaran Bayat¹, Ira Targoff⁴, Terri H Finkel⁵, Ellen Goldmuntz⁶, Michael Henrickson⁷, Bianca Lang⁸, Andrew Mammen⁹, Lauren M. Pachman¹⁰, Murray Passo¹¹, Terrance P. O'Hanlon¹, Frederick W. Miller¹, Michael Ward⁹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ³EcoStat, Inc., Mebane, NC, ⁴VA Medical Center, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Department of Pediatrics, Nemours Children's Health System/ Nemours Children's Hospital, Orlando, FL, ⁶NIAID, NIH, Bethesda, MD, ⁷Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, NS, Canada, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ¹¹Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC
Background/Purpose: We examined patients in a large juvenile dermatomyositis (JDM) registry for frequency of and factors associated with final corticosteroid discontinuation (Steroid DC), complete clinical…
Abstract Number: 2464 • 2018 ACR/ARHP Annual Meeting
Clinimetric and Drug Use Differences in Colombian Patients with Early and Established Rheumatoid Arthritis
Jorge Florez-Suarez¹, Paul Mendez², Edna Bermudez¹, Paola Coral² and Gerardo Quintana-Lopez^1,3, ¹Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogotá, Colombia, ²Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogota, Colombia, ³School of medicine, Universidad Nacional de Colombia, Bogotá, Colombia
Background/Purpose: Current guidelines for RA treatment are focused on the importance of defining the duration of symptoms before diagnosis to achieve better outcomes. This concept…
Abstract Number: 2504 • 2018 ACR/ARHP Annual Meeting
A More Time Under Remission Impacts in a Better Health-Related Quality of Life in Rheumatoid Arthritis Mestizo Population
Rocío Gamboa-Cárdenas¹, Manuel Ugarte-Gil^2,3, Mariela Medina-Chinchon¹, Cristina Reategui-Sokolova¹, Francisco Zevallos¹, Victor R. Pimentel-Quiroz¹, Claudia Elera-Fitzcarrald^1,4, Jose Alfaro-Lozano¹, Zoila Rodriguez-Bellido^1,5, Risto Perich-Campos^1,5 and Cesar A. Pastor-Asurza^1,5, ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Rheumatology, Universidad Científica del Sur, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Universidad Nacional Mayor de San Marcos, Lima, Peru
Background/Purpose: In Rheumatoid Arthritis (RA), sustained remission is associated with less disability (1,2) , and this outcome should be the goal in the RA treatment;…
Abstract Number: 2546 • 2018 ACR/ARHP Annual Meeting
The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib
Vibeke Strand¹, Nemanja Damjanov², Craig Scoville³, Namita Tundia⁴, Heidi S. Camp⁴, Kun Chen⁴, Jessica Suboticki⁴ and Ronald van Vollenhoven⁵, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, ³Idaho Falls Arthritis Clinic, Idaho Falls, ID, ⁴AbbVie Inc., North Chicago, IL, ⁵Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Patient-reported outcomes (PROs) in RA are important to evaluate total disease impact, although treatment decisions may often be guided by traditional physician-derived measures of…
Abstract Number: 1518 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data
Arantxa Conesa¹, Manuel Fernández², Rosa Expósito³, Jose Campos⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, Paula Rubio-Muñoz⁷, Pilar Ahijado-Guzman⁸ and Carlos M Gonzalez⁹, ¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ²Hospital Universitario de Guadalajara, Guadalajara, Spain, ³Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ⁴Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, ⁹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: To evaluate the effectiveness and safety of Certolizumab Pegol (CZP) in a real word setting in Psoriatic Arthritis (PsA) patients. Methods: Multicentric cohort of…
Abstract Number: 1838 • 2017 ACR/ARHP Annual Meeting
Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials
Mimi Kim¹, Joan T. Merrill², Kenneth C. Kalunian³, Leslie Hanrahan⁴ and Peter M. Izmirly⁵, ¹Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁴Lupus Foundation of America, Washington DC, DC, ⁵Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: The primary endpoint in SLE trials is usually response to therapy at a landmark visit. However, during a trial, patients may alternate between response…
Abstract Number: 2371 • 2017 ACR/ARHP Annual Meeting
The Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis Stratified By Baseline Body Mass Index
Ara Dikranian¹, Miguel Angel Gonzalez-Gay², Frank Wellborne³, Jose Maria Alvaro-Gracia⁴, Liza Takiya⁵, Lori Stockert⁵, Douglass Chapman⁶, Svitlana Tatulych⁷, Palle Dahl⁸ and Jeffrey R. Curtis⁹, ¹Cabrillo Center for Rheumatic Disease, San Diego, CA, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Houston Institute for Clinical Research, Houston, TX, ⁴Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Ballerup, Denmark, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post-hoc analysis aims to explore the efficacy of tofacitinib…
Abstract Number: 2454 • 2017 ACR/ARHP Annual Meeting
Real-World Consistency of Response to Adalimumab over Time in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas^1,2, George W. Reed^2,3, Chitra Karki⁴, Jenny Griffith⁵, Martha Skup⁵, Vishvas Garg⁵ and Joel Kremer^2,6, ¹Columbia University, New York, NY, ²Corrona LLC, Southborough, MA, ³UMass Medical School, Worcester, MA, ⁴Corrona, LLC, Southborough, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Adalimumab (ADA) was approved in the US in 2002 for rheumatoid arthritis (RA), and subsequently approved for the management of other inflammatory diseases such…
Abstract Number: 2487 • 2017 ACR/ARHP Annual Meeting
Comparison the Long-Term Clinical Outcomes between Non Anti-TNF Versus Anti-TNF in RA Patients Who Failed to a First Anti-TNF
Patricia Bogas¹, Chamaida Plasencia-Rodriguez¹, Alejandro Balsa¹, Victoria Navarro-Compán², Gema Bonilla¹, Enrique Moral Coro¹, Carolina Tornero¹, Laura Nuño¹ and Diana Peiteado³, ¹Hospital Universitario La Paz, Madrid, Spain, ²Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: There are many biological therapies for Rheumatoid Arthritis (RA) with different mechanisms of action and good efficacy rate; however, up to 40% of patients…
Abstract Number: 2602 • 2017 ACR/ARHP Annual Meeting
Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients
Hiurma Sanchez-Perez¹ and David A. Isenberg², ¹Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Response to Rituximab (RTX) varies significantly between Systemic Lupus Erythematosus (SLE) patients. Ethnicity may play a role in these differences, and a possible relationship…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].